Literature DB >> 18363756

Erysipelas as a sign of subclinical primary lymphoedema: a prospective quantitative scintigraphic study of 40 patients with unilateral erysipelas of the leg.

R J Damstra1, M A M van Steensel, J H B Boomsma, P Nelemans, J C J M Veraart.   

Abstract

BACKGROUND: Erysipelas is a common skin infection that is usually caused by beta-haemolytic group A streptococci. After having had erysipelas in an extremity, a significant percentage of patients develops persistent swelling or suffers from recurrent erysipelas. We hypothesize that in cases of erysipelas without a clear precipitating agent, subclinical pre-existing congenital or acquired disturbances in the function of the lymphatic system are present. The persistent swelling after erysipelas is then most likely caused by lymphoedema.
OBJECTIVES: We designed a study to examine if erysipelas of unknown origin is associated with a pre-existent insufficiency of the lymphatic system. If our hypothesis is correct, patients with erysipelas of unknown cause without previously evident lymphoedema should have evidence of disturbed lymphatic transport in the unaffected extremity.
METHODS: A prospective study, in which lymphoscintigraphy of both legs was performed in patients 4 months after presenting with an episode of erysipelas only in one leg. No patient had any known risk factor for erysipelas, such as diabetes mellitus, chronic venous insufficiency or clinical signs of lymphoedema. Lymphoscintigraphy was performed in 40 patients by subcutaneous injection of Tc-99m-labelled human serum albumin in the first web space of both feet. After 30 and 120 min, quantitative and qualitative scans were performed using a computerized gamma camera. During the lymphoscintigraphy, the patients performed a standardized exercise programme. Lymph drainage was quantified as the percentage uptake of Tc-99m-labelled human serum albumin in the groin nodes at 2 h after injection. Groin uptake of < 15% is pathological; uptake between 15-20% is defined as borderline, and uptake of > 20% as normal.
RESULTS: The mean +/- SD percentage uptake in the groin nodes in the affected limbs was 9.6 +/- 8.5% vs. 12.1% +/- 8.9% in the nonaffected limbs. The mean paired difference in uptake between the nonaffected vs. affected side was 2.5% (95% confidence interval 1.1-3.9%). This indicates that lymphatic drainage in the nonaffected limb was only slightly better than in the affected limb despite the infectious event in the latter. Of 33 patients with objective impairment of lymph drainage in the affected limb, 26 (79%) also had impaired lymph drainage in the nonaffected limb. Agreement in qualitative measurements between affected and nonaffected leg was less pronounced: 21 patients had abnormal qualitative results in the affected leg of whom nine also had impairment of the nonaffected leg (43%).
CONCLUSIONS: Erysipelas is often presumed to be purely infectious in origin, with a high rate of recurrence and a risk of persistent swelling due to secondary lymphoedema. In this study, we show that patients presenting with a first episode of erysipelas often have signs of pre-existing lymphatic impairment in the other, clinically nonaffected, leg. This means that subclinical lymphatic dysfunction of both legs may be an important predisposing factor. Therefore, we recommend that treatment of erysipelas should focus not only on the infection but also on the lymphological aspects, and long-standing treatment for lymphoedema is essential in order to prevent recurrence of erysipelas and aggravation of the pre-existing lymphatic impairment. Our study may change the clinical and therapeutic approach to erysipelas as well as our understanding of its aetiology.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18363756     DOI: 10.1111/j.1365-2133.2008.08503.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  9 in total

Review 1.  New developments in clinical aspects of lymphatic disease.

Authors:  Peter S Mortimer; Stanley G Rockson
Journal:  J Clin Invest       Date:  2014-03-03       Impact factor: 14.808

2.  Methicillin-resistant Staphylococcus aureus causes sustained collecting lymphatic vessel dysfunction.

Authors:  Dennis Jones; Eelco F J Meijer; Cedric Blatter; Shan Liao; Ethel R Pereira; Echoe M Bouta; Keehoon Jung; Shan Min Chin; Peigen Huang; Lance L Munn; Benjamin J Vakoc; Michael Otto; Timothy P Padera
Journal:  Sci Transl Med       Date:  2018-01-17       Impact factor: 17.956

3.  Prophylactic antibiotics for the prevention of cellulitis (erysipelas) of the leg: results of the UK Dermatology Clinical Trials Network's PATCH II trial.

Authors:  Kim Thomas; Angela Crook; Katharine Foster; James Mason; Joanne Chalmers; John Bourke; Adam Ferguson; Nick Level; Andrew Nunn; Hywel Williams
Journal:  Br J Dermatol       Date:  2011-12-06       Impact factor: 9.302

4.  Prevalence and Epidemiological Factors Involved in Cellulitis in Korean Patients With Lymphedema.

Authors:  Sae In Park; Eun Joo Yang; Dong Kyu Kim; Ho Joong Jeong; Ghi Chan Kim; Young-Joo Sim
Journal:  Ann Rehabil Med       Date:  2016-04-25

5.  LIMPRINT: The UK Experience-Subjective Control of Swelling in Patients Attending Specialist Lymphedema Services.

Authors:  Christine J Moffatt; Vaughan Keeley; Andrew Hughes; Kath Clark; Jill Lisle; Margaret Benson; Rebecca Gaskin; Martina Sykorova; Eleanor Dring; Susie Murray; Gregoire Mercier; Isabelle Quere; Peter J Franks
Journal:  Lymphat Res Biol       Date:  2019-04       Impact factor: 2.589

6.  Lower limb chronic edema management program: Perspectives of disengaged patients on challenges, enablers and barriers to program attendance and adherence.

Authors:  Linda A M Khong; Amma Buckley; Wendy Johnson; Vinicius Cavalheri
Journal:  PLoS One       Date:  2019-11-25       Impact factor: 3.240

7.  The American Venous Forum, American Vein and Lymphatic Society and the Society for Vascular Medicine expert opinion consensus on lymphedema diagnosis and treatment.

Authors:  Fedor Lurie; Rafael D Malgor; Teresa Carman; Steven M Dean; Mark D Iafrati; Neil M Khilnani; Nicos Labropoulos; Thomas S Maldonado; Peter Mortimer; Thomas F O'Donnell; Joseph D Raffetto; Stanley G Rockson; Antonios P Gasparis
Journal:  Phlebology       Date:  2022-03-08       Impact factor: 1.701

8.  Liposuction and Controlled Compression Therapy Reduce the Erysipelas Incidence in Primary and Secondary Lymphedema.

Authors:  Tobias Karlsson; Mattias Hoffner; Håkan Brorson
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-05-06

9.  Lymph Drainage of Posttraumatic Edema of Lower Limbs.

Authors:  Ana Carolina Pereira de Godoy; Rodrigo Ocampos Troitino; Maria de Fátima Guerreiro Godoy; José Maria Pereira de Godoy
Journal:  Case Rep Orthop       Date:  2018-03-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.